COPD in Obese Patients

Features of Chronic Obstructive Pulmonary Disease Clinical Course in Obese Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04105075

Enrollment

176

Registered

2019-09-26

Start date

2018-09-09

Completion date

2019-09-20

Last updated

2019-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Copd, Obese, Obesity, Abdominal

Keywords

spirometry, inflammation, copd

Brief summary

The study included 176 patients with COPD. The first group included 88 normal weight patients with COPD: 71 men and 17 women, mean age 62.40 ± 8.83 years. The second group included 88 patients with COPD and obesity: 64 men and 24 women, mean age 62.94 ± 5.96 years. We assessed the frequency of COPD exacerbations in last 12 months, the severity of symptoms such as dyspnea, sputum production, fatigue. Spirometry, six-minute walk test and analysis of body tissue type composition were performed. BODE index was calculated. Levels of leptin, adiponectin, interleukins-4,6,8,10, interferon-γ, c-reactive protein (CRP), tumor necrosis factor receptor 1 (TNF-R1), tumor necrosis factor receptor 2 (TNF-R2), tumor necrosis factor alpha (TNF-α) were measured in blood serum.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* COPD diagnosis, informed consent for voluntary participation in the study

Exclusion criteria

* patient participation in any interventional study, * COPD exacerbation, * concomitant lung diseases, such as confirmed or suspected malignant lung disease or other respiratory disease, such as interstitial pulmonary fibrosis, tuberculosis, sarcoidosis, bronchial asthma, bronchiectasis, * concomitant diseases of other organs and systems, such as acute cardiovascular diseases, chronic kidney diseases and liver failure.

Design outcomes

Primary

Measure	Time frame	Description
Labotary tests	1 year	Levels of adiponectin (µg / ml) measured in blood serum
Simptoms	1 year	dyspnea, sputum production and fatigue
Spirometry	1 year	FEV1, % pred,FVC, % pred.,FEV1/FVC, %

Secondary

Measure	Time frame	Description
Symptroms and laboratory correlations	1 year	Statistical methods allowing to figure out associations and correlations between blood tests and symptoms

Countries

Russia

Outcome results